Pluri Inc. is in active discussions with the European Investment Bank (EIB) regarding a potential resolution for its €50 million finance agreement, which was scheduled to be repaid on June 1, 2026. The EIB has indicated that discussions are advancing constructively and are subject to its internal approval process and legal review. Pluri Inc. operates in the biotechnology/cell therapy industry and develops cell-based products for therapeutic and therapeutic-related applications.
